Year All202320222021 Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative 03-17-2023 Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders 03-15-2023 Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates 03-07-2023 Zevra Therapeutics to Present at 35th Annual Roth Conference 03-06-2023 Zevra Therapeutics Begins Trading as ZVRA 03-01-2023 Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD) 02-28-2023 Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy 02-27-2023 Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results 02-27-2023 Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023 02-24-2023 Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023 02-23-2023
Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative 03-17-2023
Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates 03-07-2023
Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD) 02-28-2023
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023 02-24-2023
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023 02-23-2023
